PERIMETER MED IMAGING AI - PYNKF STOCK NEWS

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK, OTC:PYNKF) has announced its participation in several upcoming medical conferences. These include the Society of Surgical Oncology’s International Conference in Dallas, TX (March 9-12, 2022), featuring a spotlight presentation on intraoperative margin visualization, and the National Consortium of Breast Centers’ Interdisciplinary Breast Center Conference in Las Vegas, NV (March 11-16, 2022). The company aims to showcase its advanced imaging tools designed to enhance cancer surgery outcomes. Further details can be found on Perimeter’s investors' website.

Perimeter Medical Imaging AI, Inc. (PYNKF) announces CEO Jeremy Sobotta will participate in the 34th Annual Roth Conference from March 13-15, 2022, in Dana Point, CA. Sobotta will hold one-on-one investor meetings and join a panel titled “Looking to Canadian Markets for Access to Public Venture Capital and Growth Investment Opportunities.” This event will showcase insights from companies leveraging public venture capital for growth. The discussion is scheduled for March 14, 2022, at 12:30 PM PT and will be webcast for broader access.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK, OTC:PYNKF) announced key milestones in a corporate update, highlighting its FDA 510(k) clearance for the Perimeter S-Series OCT platform, enabling commercial launch. CEO Jeremy Sobotta noted a successful equity financing of C$48.7 million, boosting growth potential. The company initiated a multi-center clinical trial for the Perimeter B-Series OCT with ImgAssist AI, expected to complete in 2022. With strong backing from investors like Social Capital, Perimeter is set to advance its innovative imaging technologies in cancer surgery.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced a corporate update and conference call scheduled for February 23, 2022, at 5 PM ET, led by CEO Jeremy Sobotta. The company, focused on transforming cancer surgery with advanced imaging technology, aims to address significant medical needs. The conference can be accessed via phone or an audio webcast. This session will provide investors with insights into the company’s developments in high-resolution imaging tools designed to assist in the fight against breast cancer.

Perimeter Medical Imaging AI, Inc. has completed a private placement of units, raising C$48.7 million. This includes a strategic investment of C$43.4 million from Social Capital, acquiring approximately 23.3% of Perimeter's outstanding shares. The funds will support commercialization efforts and ongoing clinical development. Each unit consists of one common share and a warrant, with strike prices set at C$3.99 and C$4.50. All securities issued are subject to a hold period until May 27, 2022.

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) announces the expansion of its pivotal clinical trial at Baylor College of Medicine in Houston, TX. The study evaluates the Perimeter B-Series OCT imaging platform combined with ImgAssist AI to improve margin assessment during breast conservation surgeries. Approximately 300 patients at eight U.S. sites are involved, with completion expected by late 2022. The FDA has granted Breakthrough Device Designation for this technology, aimed at aiding surgeons in real-time decision-making to reduce re-operations and healthcare costs.

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) has successfully completed the first commercial installation of its Perimeter S-Series Optical Coherence Tomography (OCT) system in a North Texas hospital. This advanced imaging technology offers high-resolution, real-time imaging of excised tissue, enhancing the surgeon's ability to visualize margins during cancer surgery. CEO Jeremy Sobotta emphasized this milestone as a validation of their market strategy. The S-Series OCT system, cleared by the FDA, could lead to better patient outcomes and reduced healthcare costs.

Perimeter Medical Imaging AI, Inc. has launched a pivotal clinical trial evaluating its Perimeter B-Series OCT with ImgAssist AI for breast conservation surgery. Conducted at the Margaret West Comprehensive Breast Center, the trial aims to assess the technology's effect on positive margin rates, which currently require reoperation in 15-20% of cases. With a $7.4 million grant from CPRIT and FDA Breakthrough Device Designation, this study marks a crucial step towards improving surgical outcomes. The trial anticipates completion by the end of 2022.